New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Gregor Reid, Ph.D and Andrew Bruce, MD, FRCS(C), Developers of Lactobacillus Strains GR-1™ and RC-14®, Win Prestigious Metchnikoff Prize

Los Angeles, CA, June 8, 2007 – Canadian Scientists Gregor Reid, Ph.D and Andrew Bruce, MD, FRCS(C), have won the prestigious Metchnikoff Prize for discovering and developing Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14®. These strains, the world's most documented probiotic strains for women's health, are featured in Jarrow Formulas’ Fem-Dophilus. Fem-Dophilus is the only oral probiotic product backed by clinical research for restoring and maintaining a healthy vaginal flora and supporting urinary tract health. Jarrow Formulas’ Fem-Dophilus is produced and marketed globally by Chr. Hansen, a world leader in probiotics.

Dr. Reid, Director of the Canadian Research and Development Centre for Probiotics and Professor at the University of Western Ontario, and Dr. Bruce, former Chairman of Urology at the University of Toronto, received the award on May 17, 2007 at the International Dairy Federation Conference in Moscow. The Canadian researchers were chosen from 31 nominees from 17 countries, in one of the three winning categories, and were cited as scientists who have made outstanding discoveries in how lactic acid bacteria and probiotics enhance human nutrition, health and longevity.
Every year, more than 45 million American women suffer from bacterial vaginosis, bladder infections and yeast vaginitis. More than 25 years of research has confirmed that GR-1™ and RC-14®, taken as an oral supplement, acts naturally to protect the vaginal and urinary tracts to enhance personal health in women of all ages.

Patented Fem-Dophilus is manufactured at a Good Manufacturing Practices (GMP) pharmaceutical facility under strict quality control to ensure potency and consistency. The probiotic strains in Fem-Dophilus are in a proprietary polysaccharide matrix, which protects the bacteria from gastric acids and bile and thus enhances probiotic bacteria survival into the lower intestine.

Dr. Reid is originally from Scotland where he obtained a BSc Honors and holds a Ph.D in Microbiology from Massey University in New Zealand and MBA from Monash University in Australia. After spells at the University of Calgary and the University of Toronto, he is now Assistant Director at the Lawson Health Research Institute in London, Canada, and President of the International Scientific Association for Probiotics and Prebiotics. Dr. Reid has published more than 300 peer-reviewed papers, mostly on probiotics and urinary tract infections. He has presented more than 350 seminars in 37 countries. He has been the Chair of the United Nations/World Health Organization Expert Consultation and Working Group on Probiotics, and has been a reviewer for 62 journals and 30 international agencies (including NIH). Drs. Reid and Bruce jointly hold 28 patents.

Dr. Bruce is currently Emeritus Professor of Urology at the University of Toronto, and Affiliate Scientist at the Lawson Health Research Institute. He graduated in medicine in Aberdeen, Scotland and received his surgical and urological training in Aberdeen and London, England. In Canada, Dr. Bruce was Chairman of Urology at Queens University in Kingston, Ontario, went on to become the Chairman of Urology at McGill University in Montreal and then proceeded to take the position of Chairman of Urology at the University of Toronto. He has had a major interest in probiotic basic and clinical research over the past 30 years, with specific attention directed to urogenital infections in women, and has been involved in many research studies, resulting in more than 200 scientific publications. He is currently involved in further clinical studies and application of probiotic technologies to benefit women worldwide.

Jarrow Formulas is a nutritional supplement formulator and marketer founded in 1977 and incorporated in 1988. The company markets its products throughout the United States and internationally in more than 20 countries in Europe, Asia, Israel and Latin America. The company offers a complete line of nutritional products that includes vitamins, minerals, probiotics, standardized herbal concentrates, amino acids, enzymes and enteral nutrition formulations. Jarrow Formulas, Inc. is active in regulatory affairs, helping to maintain American’s rights to free access to dietary supplements. Its products are manufactured by Jarrow Industries Incorporated, a pharmaceutical quality facility located in Santa Fe Springs, CA. For more information, contact Mark Becker, Director, Advertising/Communications toll free at (800) 726-0886 or access the Jarrow Formulas Web site at

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.